FDA 483 - Samsung Biologics Co., Ltd. - May 27, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Samsung Biologics Co., Ltd. in Yeonsu Incheon, Korea, a drug substance manufacturer, was cited for significant deficiencies across multiple areas during an FDA inspection. Observations included failures to follow cross-contamination prevention procedures, widespread data integrity issues within the quality control unit, and inadequate quality control laboratory procedures for drug substance testing and waste disposal. Additionally, the firm implemented changes to an approved application and released drug substance batches without prior FDA approval.
ID · b3a6afca-acc1-42d3-9eaa-a9c039d1bb0a